Spotlight on Cardiology
Spotlight Series: Unmet Needs in Hypertension Treatment Options
StartActivity Details
1.0 ABIM MOC point(s)
1.0 ANCC Contact Hour(s)
Expires: January 30, 2024
Accredited By
ACCME (AMA PRA Category 1 Credit™), ANCC
Target Audience
- General Cardiologists
- Nephrologists
- Hypertension Specialists
- Internal Medicine Physicians
- Primary Care/Family Medicine Physicians
- Physician Assistants involved in the care of patients with hypertension
- Nurse Practitioners involved in the care of patients with hypertension
- Nurses involved in the care of patients with hypertension
Learning Objectives
- Recognize established and emerging treatment options for patients with resistant hypertension.
- Identify healthcare disparities in care provided to patients with hypertension.
- Apply shared decision-making strategies to improve health equity by better engaging patients in health care decisions through the development of improved patient-provider communication skills.
Activity Description
Hypertension increases with age and treatment-resistant hypertension exists within the US population.
Participants in this activity will learn about treatment options for patients with resistant hypertension, how to address healthcare disparities in treatment and management, and shared decision-making strategies to improve health equity.
Statement of Educational Need
It is estimated 10.3 million US adults have apparent treatment-resistant hypertension.1 The overall goal of the intervention is to increase healthcare professionals’ (HCP) awareness, knowledge, and competence in managing unmet needs in hypertension treatment. AHA Lifelong Learning will achieve this goal by addressing educational needs and practice gaps that exist among a multidisciplinary team of HCPs involved in the care of patients with hypertension. The intervention will promote application of education into practice, providing learners with knowledge and skills they can put into practice immediately to impact patient outcomes.
- Carey RM, Sakhuja S, Calhoun DA, et al. Prevalence of Apparent Treatment-Resistant Hypertension in the United States. Hypertension. 2019;73(2):424-431
Agenda
- Spotlight Series: Unmet Needs in Hypertension Treatment Options - presentation
- Q & A
Presenter – Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
Faculty
Gerald S. Berenson Endowed Chair in Preventive Cardiology
Professor of Medicine, John W. Deming Department of Medicine
Tulane University School of Medicine
New Orleans, LA
Disclosure Policy
All persons in a position to control educational content of a CE activity provided by the American Heart Association must disclose to the audience all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The presence or absence of all financial relationships will be disclosed to the audience in activity materials. All unlabeled/unapproved uses of drugs or devices discussed will also be disclosed to the audience. All relevant financial relationships have been mitigated prior to the commencement of the activity.
Disclosures
The American Heart Association (AHA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its certified educational activities. All faculty, planners, and contributors in a position to control the content for an AHA sponsored activity are required to disclose to the activity audience any financial relationships regardless of the amount during the prior 24 months with (1) the manufacturer(s) of any ineligible company product(s) and/or interest(s) of ineligible companies regardless of relation to the content of the activity and (2) any ineligible company supporters of the activity. When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.
Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA – Consultant (Amgen, Novartis, Medtronic, Quantum Genomics, Janssen)
Accreditation Statement
ORIGINAL RELEASE DATE: 01/31/2023
TERMINATION DATE: 01/30/2024
LAST REVIEW DATE: November 2022
ACCREDITATION TERMS: Joint Accreditation: 01/31/2023 - 01/30/2024
In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AMA Credit Designation Statement – Physicians
The American Heart Association designates this enduring activity for a
maximum of 1.0 AMA PRA Category 1 Credits™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
MOC Statement
Successful completion of this CE activity, which includes participation in
the evaluation component, enables the participant to earn up to 1.0 MOC
points in the American Board of Internal Medicine's (ABIM) Maintenance of
Certification (MOC) program. Participants will earn MOC points equivalent to
the amount of CE credits claimed for the activity. It is the CE activity
provider's responsibility to submit participant completion information to
ACCME for the purpose of granting ABIM MOC credit.
AAPA Credit Acceptance Statement – Physician
Assistants
AAPA accepts certificates of participation for educational activities
certified for AMA PRA Category 1 Credit™ from
organizations accredited by ACCME or a recognized state medical society.
Physician assistants may receive a maximum of 1.0 hours of Category I credit
for completing this program.
AANP Credit Acceptance Statement – Nurse
Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA
Category 1 Credit™ from organizations accredited by the ACCME.
ANCC Credit Designation Statement – Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact
hours.
Instructions for Receiving Credit
Participation and Successful
Completion
Successful completion of this CE activity includes the following:
- Register and view the course online.
- View the content in its entirety.
- Complete a post-test with a minimum score of 80%.
- Complete a survey of your learning experience.
- Claim your CME/CE Certificate.
Statement of Commercial Support
This activity is supported by an independent medical educational grant from Medtronic.
Disclaimer Statement/Disclosure of Unlabeled Use
When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.
Contact Information for Questions About the Activity
Luci Ochoa, MBA
Program Manager, Professional Education, AHA National Center
luci.ochoa@heart.org
Activity Details
1.0 ABIM MOC point(s)
1.0 ANCC Contact Hour(s)
Expires: January 30, 2024
Accredited By
ACCME (AMA PRA Category 1 Credit™), ANCC
Target Audience
- General Cardiologists
- Nephrologists
- Hypertension Specialists
- Internal Medicine Physicians
- Primary Care/Family Medicine Physicians
- Physician Assistants involved in the care of patients with hypertension
- Nurse Practitioners involved in the care of patients with hypertension
- Nurses involved in the care of patients with hypertension
Learning Objectives
- Recognize established and emerging treatment options for patients with resistant hypertension.
- Identify healthcare disparities in care provided to patients with hypertension.
- Apply shared decision-making strategies to improve health equity by better engaging patients in health care decisions through the development of improved patient-provider communication skills.
Activity Description
Hypertension increases with age and treatment-resistant hypertension exists within the US population.
Participants in this activity will learn about treatment options for patients with resistant hypertension, how to address healthcare disparities in treatment and management, and shared decision-making strategies to improve health equity.
Statement of Educational Need
It is estimated 10.3 million US adults have apparent treatment-resistant hypertension.1 The overall goal of the intervention is to increase healthcare professionals’ (HCP) awareness, knowledge, and competence in managing unmet needs in hypertension treatment. AHA Lifelong Learning will achieve this goal by addressing educational needs and practice gaps that exist among a multidisciplinary team of HCPs involved in the care of patients with hypertension. The intervention will promote application of education into practice, providing learners with knowledge and skills they can put into practice immediately to impact patient outcomes.
- Carey RM, Sakhuja S, Calhoun DA, et al. Prevalence of Apparent Treatment-Resistant Hypertension in the United States. Hypertension. 2019;73(2):424-431
Agenda
- Spotlight Series: Unmet Needs in Hypertension Treatment Options - presentation
- Q & A
Presenter – Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
Faculty
Gerald S. Berenson Endowed Chair in Preventive Cardiology
Professor of Medicine, John W. Deming Department of Medicine
Tulane University School of Medicine
New Orleans, LA
Disclosure Policy
All persons in a position to control educational content of a CE activity provided by the American Heart Association must disclose to the audience all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The presence or absence of all financial relationships will be disclosed to the audience in activity materials. All unlabeled/unapproved uses of drugs or devices discussed will also be disclosed to the audience. All relevant financial relationships have been mitigated prior to the commencement of the activity.
Disclosures
The American Heart Association (AHA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its certified educational activities. All faculty, planners, and contributors in a position to control the content for an AHA sponsored activity are required to disclose to the activity audience any financial relationships regardless of the amount during the prior 24 months with (1) the manufacturer(s) of any ineligible company product(s) and/or interest(s) of ineligible companies regardless of relation to the content of the activity and (2) any ineligible company supporters of the activity. When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.
Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA – Consultant (Amgen, Novartis, Medtronic, Quantum Genomics, Janssen)
Accreditation Statement
ORIGINAL RELEASE DATE: 01/31/2023
TERMINATION DATE: 01/30/2024
LAST REVIEW DATE: November 2022
ACCREDITATION TERMS: Joint Accreditation: 01/31/2023 - 01/30/2024
In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AMA Credit Designation Statement – Physicians
The American Heart Association designates this enduring activity for a
maximum of 1.0 AMA PRA Category 1 Credits™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
MOC Statement
Successful completion of this CE activity, which includes participation in
the evaluation component, enables the participant to earn up to 1.0 MOC
points in the American Board of Internal Medicine's (ABIM) Maintenance of
Certification (MOC) program. Participants will earn MOC points equivalent to
the amount of CE credits claimed for the activity. It is the CE activity
provider's responsibility to submit participant completion information to
ACCME for the purpose of granting ABIM MOC credit.
AAPA Credit Acceptance Statement – Physician
Assistants
AAPA accepts certificates of participation for educational activities
certified for AMA PRA Category 1 Credit™ from
organizations accredited by ACCME or a recognized state medical society.
Physician assistants may receive a maximum of 1.0 hours of Category I credit
for completing this program.
AANP Credit Acceptance Statement – Nurse
Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA
Category 1 Credit™ from organizations accredited by the ACCME.
ANCC Credit Designation Statement – Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact
hours.
Instructions for Receiving Credit
Participation and Successful
Completion
Successful completion of this CE activity includes the following:
- Register and view the course online.
- View the content in its entirety.
- Complete a post-test with a minimum score of 80%.
- Complete a survey of your learning experience.
- Claim your CME/CE Certificate.
Statement of Commercial Support
This activity is supported by an independent medical educational grant from Medtronic.
Disclaimer Statement/Disclosure of Unlabeled Use
When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.
Contact Information for Questions About the Activity
Luci Ochoa, MBA
Program Manager, Professional Education, AHA National Center
luci.ochoa@heart.org
Cardiology Presentations
Developing an Amyloidosis Center of Excellence: Path to Success and Overcoming Challenges
StartActivity Details
1.0 ABIM MOC point(s)
1.0 ANCC Contact Hour(s)
1.0 ACPE Contact Hour(s)
1.0 AAFP Prescribed Credit(s)
Expires: TBD
Accredited By
ACCME (AMA PRA Category 1 Credit™), ANCC
Target Audience
General Cardiology, Heart Failure, Neurology, Echocardiography, Nuclear Cardiology, Primary Care, and other specialties involved in the care of patients diagnosed with ATTR-CM.
Learning Objectives
- Identify strategies to develop a center of excellence to improve the quality of care for cardiac amyloidosis patients.
- Apply the steps required to provide leadership, best practices, support and/or training of health care professionals within a multidisciplinary environment of a cardiac amyloid center.
- Recognize the challenges in developing a center of excellence to improve the quality of care for cardiac amyloidosis patients.
Activity Description
The webinar discusses steps to develop a center of excellence to provide leadership, best practices, support and/or training of HCPs within a multidisciplinary team environment to improve the quality of care for cardiac amyloidosis patients as well as challenges that may occur.
Statement of Educational Need
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a restrictive cardiomyopathy produced by extracellular deposition of transthyretin, typically involved in the conveyance of the hormone thyroxine and retinol-binding protein, in the myocardium. ATTR-CM interest has increased as a result of progress in three simultaneous areas. These include imaging techniques, which allow for accurate noninvasive diagnosis of ATTR-CM without the need for endomyocardial biopsies; observational studies, which have shown ATTR-CM diagnosis may be underrecognized in a significant proportion of heart failure patients; and with the clarification of the mechanisms of amyloid formation, therapies have now been approved for treatment of ATTR-CM. Early detection with readily available noninvasive tests is essential as therapy for ATTR-CM may be most effective when administered before significant cardiac dysfunction.1
- Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac Amyloidosis: Evolving Diagnosis and Management. A Scientific Statement from the American Heart Association. Circulation. 2020; 142:e7–e22. DOI: 10.1161/CIR.0000000000000792.
Agenda
- Developing an Amyloidosis Center of Excellence: Path to Success and Overcoming Challenges - presentation
- Q & A
Presenters – Johana Farjardo, DNP, ANP-BC CHFN FHFSA, Jose Nativi-Nicolau,
MD, MS, FACC, FHFSA
Moderator - Katherine E. Di Palo, PharmD, MBA, MS
Moderator
Katherine E. Di
Palo, PharmD, MBA, MSPresenters
Jose
Nativi-Nicolau, MD, MS, FACC, FHFSA
Johana Farjardo, DNP,
ANP-BC CHFN FHFSADisclosure Policy
All persons in a position to control educational content of a CE activity provided by the American Heart Association must disclose to the audience all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The presence or absence of all financial relationships will be disclosed to the audience in activity materials. All unlabeled/unapproved uses of drugs or devices discussed will also be disclosed to the audience. All relevant financial relationships have been mitigated prior to the commencement of the activity.
Disclosures
The American Heart Association (AHA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its certified educational activities. All faculty, planners, and contributors in a position to control the content for an AHA sponsored activity are required to disclose to the activity audience any financial relationships regardless of the amount during the prior 24 months with (1) the manufacturer(s) of any ineligible company product(s) and/or interest(s) of ineligible companies regardless of relation to the content of the activity and (2) any ineligible company supporters of the activity. When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.
Faculty
Katherine E. Di Palo, PharmD, MBA, MS – No Disclosures
Jose Nativi-Nicolau, MD, MS, FACC, FHFSA – Consultant/Advisory Board (Pfizer,
Alnylam, Ionis/Akcea)
Johana Farjardo, DNP, ANP-BC CHFN FHFSA – No Disclosures
Accreditation Statement
ORIGINAL RELEASE DATE: 02/08/2023
TERMINATION DATE: 02/07/2024
LAST REVIEW DATE: November 2022
ACCREDITATION TERMS: Joint Accreditation: 02/08/2023 - 02/07/2024
In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AMA Credit Designation Statement – Physicians
The American Heart Association designates this activity for a maximum of
1.00 AMA PRA Category 1 Credits™. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
MOC Statement
Successful completion of this CE activity, which includes participation in
the evaluation component, enables the participant to earn up to 1.00 MOC
points in the American Board of Internal Medicine's (ABIM) Maintenance of
Certification (MOC) program. Participants will earn MOC points equivalent to
the amount of CE credits claimed for the activity. It is the CE activity
provider's responsibility to submit participant completion information to
ACCME for the purpose of granting ABIM MOC credit.
AAPA Credit Acceptance Statement – Physician
Assistants
AAPA accepts certificates of participation for educational activities
certified for AMA PRA Category 1 Credit™ from
organizations accredited by ACCME or a recognized state medical society.
Physician assistants may receive a maximum of 1.00 hours of Category I
credit for completing this program.
AANP Credit Acceptance Statement – Nurse
Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA
Category 1 Credit™ from organizations accredited by the ACCME.
ANCC Credit Designation Statement – Nurses
The maximum number of hours awarded for this CE activity is 1.00 contact
hours.
ACPE Credit Designation Statement – Pharmacists
ACPE Credit: 1.00 Contact Hours. Universal Program
Number: JA0000134-0000-22-098-H04-P
AAFP Credit Designation Statement – Physicians
The AAFP has reviewed Improving Care of Patients with Transthyretin
Cardiomyopathy - Enduring and deemed it acceptable for AAFP credit. Term of
approval is from 04/07/2022 to 04/07/2023. Physicians should claim only the
credit commensurate with the extent of their participation in the activity.
This session Developing an Amyloidosis Center of Excellence: Path to Success
and Overcoming Challenges is approved for 1 credit enduring webinar AAFP
Prescribed credit. Term of approval for this session is 02/08/2023 to
02/07/2024.
Instructions for Receiving Credit
Participation and Successful Completion
Successful completion of this CE activity
includes the following:
- Register and view the course online.
- View the content in its entirety.
- Complete a post-test with a minimum score of 80%.
- Complete a survey of your learning experience.
- Claim your CE Certificate.
Statement of Commercial Support
This activity is supported by an independent medical educational grant from Pfizer.
Disclaimer Statement/Disclosure of Unlabeled Use
When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.
Contact Information for Questions About the Activity
Luci Ochoa, MBA
Program Manager, Professional Education, AHA National Center
luci.ochoa@heart.org
Activity Details
1.0 ABIM MOC point(s)
1.0 ANCC Contact Hour(s)
1.0 ACPE Contact Hour(s)
1.0 AAFP Prescribed Credit(s)
Expires: TBD
Accredited By
ACCME (AMA PRA Category 1 Credit™), ANCC
Target Audience
General Cardiology, Heart Failure, Neurology, Echocardiography, Nuclear Cardiology, Primary Care, and other specialties involved in the care of patients diagnosed with ATTR-CM.
Learning Objectives
- Identify strategies to develop a center of excellence to improve the quality of care for cardiac amyloidosis patients.
- Apply the steps required to provide leadership, best practices, support and/or training of health care professionals within a multidisciplinary environment of a cardiac amyloid center.
- Recognize the challenges in developing a center of excellence to improve the quality of care for cardiac amyloidosis patients.
Activity Description
The webinar discusses steps to develop a center of excellence to provide leadership, best practices, support and/or training of HCPs within a multidisciplinary team environment to improve the quality of care for cardiac amyloidosis patients as well as challenges that may occur.
Statement of Educational Need
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a restrictive cardiomyopathy produced by extracellular deposition of transthyretin, typically involved in the conveyance of the hormone thyroxine and retinol-binding protein, in the myocardium. ATTR-CM interest has increased as a result of progress in three simultaneous areas. These include imaging techniques, which allow for accurate noninvasive diagnosis of ATTR-CM without the need for endomyocardial biopsies; observational studies, which have shown ATTR-CM diagnosis may be underrecognized in a significant proportion of heart failure patients; and with the clarification of the mechanisms of amyloid formation, therapies have now been approved for treatment of ATTR-CM. Early detection with readily available noninvasive tests is essential as therapy for ATTR-CM may be most effective when administered before significant cardiac dysfunction.1
- Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac Amyloidosis: Evolving Diagnosis and Management. A Scientific Statement from the American Heart Association. Circulation. 2020; 142:e7–e22. DOI: 10.1161/CIR.0000000000000792.
Agenda
- Developing an Amyloidosis Center of Excellence: Path to Success and Overcoming Challenges - presentation
- Q & A
Presenters – Johana Farjardo, DNP, ANP-BC CHFN FHFSA, Jose Nativi-Nicolau,
MD, MS, FACC, FHFSA
Moderator - Katherine E. Di Palo, PharmD, MBA, MS
Moderator
Katherine E. Di
Palo, PharmD, MBA, MSPresenters
Jose
Nativi-Nicolau, MD, MS, FACC, FHFSA Johana Farjardo, DNP,
ANP-BC CHFN FHFSADisclosure Policy
All persons in a position to control educational content of a CE activity provided by the American Heart Association must disclose to the audience all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The presence or absence of all financial relationships will be disclosed to the audience in activity materials. All unlabeled/unapproved uses of drugs or devices discussed will also be disclosed to the audience. All relevant financial relationships have been mitigated prior to the commencement of the activity.
Disclosures
The American Heart Association (AHA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its certified educational activities. All faculty, planners, and contributors in a position to control the content for an AHA sponsored activity are required to disclose to the activity audience any financial relationships regardless of the amount during the prior 24 months with (1) the manufacturer(s) of any ineligible company product(s) and/or interest(s) of ineligible companies regardless of relation to the content of the activity and (2) any ineligible company supporters of the activity. When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.
Faculty
Katherine E. Di Palo, PharmD, MBA, MS – No Disclosures
Jose Nativi-Nicolau, MD, MS, FACC, FHFSA – Consultant/Advisory Board (Pfizer,
Alnylam, Ionis/Akcea)
Johana Farjardo, DNP, ANP-BC CHFN FHFSA – No Disclosures
Accreditation Statement
ORIGINAL RELEASE DATE: 02/08/2023
TERMINATION DATE: 02/07/2024
LAST REVIEW DATE: November 2022
ACCREDITATION TERMS: Joint Accreditation: 02/08/2023 - 02/07/2024
In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AMA Credit Designation Statement – Physicians
The American Heart Association designates this activity for a maximum of
1.00 AMA PRA Category 1 Credits™. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
MOC Statement
Successful completion of this CE activity, which includes participation in
the evaluation component, enables the participant to earn up to 1.00 MOC
points in the American Board of Internal Medicine's (ABIM) Maintenance of
Certification (MOC) program. Participants will earn MOC points equivalent to
the amount of CE credits claimed for the activity. It is the CE activity
provider's responsibility to submit participant completion information to
ACCME for the purpose of granting ABIM MOC credit.
AAPA Credit Acceptance Statement – Physician
Assistants
AAPA accepts certificates of participation for educational activities
certified for AMA PRA Category 1 Credit™ from
organizations accredited by ACCME or a recognized state medical society.
Physician assistants may receive a maximum of 1.00 hours of Category I
credit for completing this program.
AANP Credit Acceptance Statement – Nurse
Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA
Category 1 Credit™ from organizations accredited by the ACCME.
ANCC Credit Designation Statement – Nurses
The maximum number of hours awarded for this CE activity is 1.00 contact
hours.
ACPE Credit Designation Statement – Pharmacists
ACPE Credit: 1.00 Contact Hours. Universal Program
Number: JA0000134-0000-22-098-H04-P
AAFP Credit Designation Statement – Physicians
The AAFP has reviewed Improving Care of Patients with Transthyretin
Cardiomyopathy - Enduring and deemed it acceptable for AAFP credit. Term of
approval is from 04/07/2022 to 04/07/2023. Physicians should claim only the
credit commensurate with the extent of their participation in the activity.
This session Developing an Amyloidosis Center of Excellence: Path to Success
and Overcoming Challenges is approved for 1 credit enduring webinar AAFP
Prescribed credit. Term of approval for this session is 02/08/2023 to
02/07/2024.
Instructions for Receiving Credit
Participation and Successful Completion
Successful completion of this CE activity
includes the following:
- Register and view the course online.
- View the content in its entirety.
- Complete a post-test with a minimum score of 80%.
- Complete a survey of your learning experience.
- Claim your CE Certificate.
Statement of Commercial Support
This activity is supported by an independent medical educational grant from Pfizer.
Disclaimer Statement/Disclosure of Unlabeled Use
When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.
Contact Information for Questions About the Activity
Luci Ochoa, MBA
Program Manager, Professional Education, AHA National Center
luci.ochoa@heart.org
Spotlight Series: Improving Outcomes for Patients with Atrial Fibrillation
StartActivity Details
0.75 ABIM MOC point(s)
0.75 ANCC Contact Hour(s)
0.75 ACPE Contact Hour(s)
Expires: February 6, 2024
Accredited By
ACCME (AMA PRA Category 1 Credit™), ANCC
Target Audience
Clinical Cardiologists
Interventional Cardiologists
Electrophysiologists
Hospitalists
Internal Medicine Physicians
Family Practice/General Practice Physicians
Physician Assistants
Nurse Practitioners
Nurses
Pharmacists
Learning Objectives
- Apply current national and international guidelines and medical evidence for the management of patients with atrial fibrillation in clinical practice.
- Discuss the underutilization and risk/benefit of anticoagulation and antiarrhythmics in patients with atrial fibrillation (AF).
- Discuss pharmacologic treatments for AF, including the appropriate use of rate vs rhythm control.
- Identify non-pharmacologic treatments, for patients with AF and integrate their use into clinical practice.
- Describe the importance of lifestyle modification for the treatment/prevention of atrial fibrillation.
- Identify racial/ethnic differences in the treatment/management of patients with AF and opportunities to overcome them in clinical practice.
Activity Description
This case-based presentation is designed to provide learners with the evidence and knowledge they require to incorporate guideline-based care and new research findings into their management of patients with AF, including the appropriate use of rate and rhythm control options, anticoagulants, anti-arhythmic drugs, lifestyle approaches, and non-pharmacologic therapies, as well as understand ethnic/racial differences in outcomes for AF.
Statement of Educational Need
AFib Incidence & Prevalence
Cardiac rhythm disorders are common, with atrial fibrillation (AFib) being
the most common form of arrhythmia. The prevalence of AFib in the United
States (US) is estimated to rise from ≈5.2 million in 2010 to 12.1 million in
2030. Data from a health insurance claims database covering 5% of the US
found the incidence of AFib was estimated at 1.2 million new cases in 2010
and projected it to increase to 2.6 million new cases in 2030. The lifetime
risk of AFib in the US is about ≈1 in 3 in Whites and ≈1 in 5 in Blacks. Even
with current guideline-based management, AFib patients have stroke, acute
coronary syndrome, heart failure, and cardiovascular death at a rate of
approximately 5% of patients per year, and 35 to 50% of patients with AFib
who receive adequate anticoagulation either receive inpatient therapy or die
within 5 years. (1)
Anticoagulants & Ablation
In 2019, the American Heart Association/American College of Cardiology/Heart
Rhythm Society (AHA/ACC/HRS) updated their AFib Guidelines to strongly
recommend using direct oral anticoagulants (DOACs), also called novel oral
anticoagulants (NOACs), over warfarin to prevent blood clots in people with
AFib. (2)
(1) Virani SS, et al. Heart Disease and Stroke Statistics-2021 Update: A Report from the American Heart Association. Circulation 2021. (2) Zimetbaum P. DOACs now recommended over warfarin to prevent blood clots in people with atrial fibrillation. Harvard Health Publishing 2019.
Agenda
- Spotlight Series: Improving Outcomes for Patients with Atrial Fibrillation - presentation
- Q & A
Presenter – Rakesh Gopinathannair, MD, MA, FAHA, FACC, FHRS
Faculty
Rakesh
Gopinathannair, MD, MA, FAHA, FACC, FHRSCardiac EP Lab Director, Kansas City Heart Rhythm Institute
Professor of Medicine, University of Missouri-Columbia
Disclosure Policy
All persons in a position to control educational content of a CE activity provided by the American Heart Association must disclose to the audience all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The presence or absence of all financial relationships will be disclosed to the audience in activity materials. All unlabeled/unapproved uses of drugs or devices discussed will also be disclosed to the audience. All relevant financial relationships have been mitigated prior to the commencement of the activity.
Disclosures
The American Heart Association (AHA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its certified educational activities. All faculty, planners, and contributors in a position to control the content for an AHA sponsored activity are required to disclose to the activity audience any financial relationships regardless of the amount during the prior 24 months with (1) the manufacturer(s) of any ineligible company product(s) and/or interest(s) of ineligible companies regardless of relation to the content of the activity and (2) any ineligible company supporters of the activity. When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.
Rakesh Gopinathannair, MD, MA, FAHA, FACC, FHRS - Consultant/speaker: Abbott Medical, Boston Scientific, Biotronik, Zoll Medical; Advisory Board: Altathera, PaceMate (no compensation)
Accreditation Statement
ORIGINAL RELEASE DATE: 02/07/2023
TERMINATION DATE: 02/06/2024
LAST REVIEW DATE: November 2022
ACCREDITATION TERMS: Joint Accreditation: 02/07/2023 - 02/06/2024
In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AMA Credit Designation Statement – Physicians
The American Heart Association designates this enduring activity for a
maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
MOC Statement
Successful completion of this CE activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.75 MOC
points in the American Board of Internal Medicine's (ABIM) Maintenance of
Certification (MOC) program. Participants will earn MOC points equivalent to
the amount of CE credits claimed for the activity. It is the CE activity
provider's responsibility to submit participant completion information to
ACCME for the purpose of granting ABIM MOC credit.
AAPA Credit Acceptance Statement – Physician
Assistants
AAPA accepts certificates of participation for educational activities
certified for AMA PRA Category 1 Credit™ from organizations
accredited by ACCME or a recognized state medical society. Physician
assistants may receive a maximum of 0.75 hours of Category I credit for
completing this program.
AANP Credit Acceptance Statement – Nurse
Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA
Category 1 Credit™ from organizations accredited by the ACCME.
ANCC Credit Designation Statement – Nurses
The maximum number of hours awarded for this CE activity is 0.75 contact
hours.
ACPE Credit Designation Statement – Pharmacists
ACPE Credit: 0.75 Contact Hours. Universal Program
Number: JA0000134-0000-22-100-H04-P
Instructions for Receiving Credit
Participation and Successful
Completion
Successful completion of this CE activity includes the following:
- Register and view the course online.
- View the content in its entirety.
- Complete a post-test with a minimum score of 80%.
- Complete a survey of your learning experience.
- Claim your CME/CE Certificate.
Statement of Commercial Support
This activity is supported by an independent medical educational grant from Sanofi US.
Disclaimer Statement/Disclosure of Unlabeled Use
When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.
Contact Information for Questions About the Activity
Luci Ochoa, MBA
Program Manager, Professional Education, AHA National Center
luci.ochoa@heart.org
Activity Details
0.75 ABIM MOC point(s)
0.75 ANCC Contact Hour(s)
0.75 ACPE Contact Hour(s)
Expires: February 6, 2024
Accredited By
ACCME (AMA PRA Category 1 Credit™), ANCC
Target Audience
Clinical Cardiologists
Interventional Cardiologists
Electrophysiologists
Hospitalists
Internal Medicine Physicians
Family Practice/General Practice Physicians
Physician Assistants
Nurse Practitioners
Nurses
Pharmacists
Learning Objectives
- Apply current national and international guidelines and medical evidence for the management of patients with atrial fibrillation in clinical practice.
- Discuss the underutilization and risk/benefit of anticoagulation and antiarrhythmics in patients with atrial fibrillation (AF).
- Discuss pharmacologic treatments for AF, including the appropriate use of rate vs rhythm control.
- Identify non-pharmacologic treatments, for patients with AF and integrate their use into clinical practice.
- Describe the importance of lifestyle modification for the treatment/prevention of atrial fibrillation.
- Identify racial/ethnic differences in the treatment/management of patients with AF and opportunities to overcome them in clinical practice.
Activity Description
This case-based presentation is designed to provide learners with the evidence and knowledge they require to incorporate guideline-based care and new research findings into their management of patients with AF, including the appropriate use of rate and rhythm control options, anticoagulants, anti-arhythmic drugs, lifestyle approaches, and non-pharmacologic therapies, as well as understand ethnic/racial differences in outcomes for AF.
Statement of Educational Need
AFib Incidence & Prevalence
Cardiac rhythm disorders are common, with atrial fibrillation (AFib) being
the most common form of arrhythmia. The prevalence of AFib in the United
States (US) is estimated to rise from ≈5.2 million in 2010 to 12.1 million in
2030. Data from a health insurance claims database covering 5% of the US
found the incidence of AFib was estimated at 1.2 million new cases in 2010
and projected it to increase to 2.6 million new cases in 2030. The lifetime
risk of AFib in the US is about ≈1 in 3 in Whites and ≈1 in 5 in Blacks. Even
with current guideline-based management, AFib patients have stroke, acute
coronary syndrome, heart failure, and cardiovascular death at a rate of
approximately 5% of patients per year, and 35 to 50% of patients with AFib
who receive adequate anticoagulation either receive inpatient therapy or die
within 5 years. (1)
Anticoagulants & Ablation
In 2019, the American Heart Association/American College of Cardiology/Heart
Rhythm Society (AHA/ACC/HRS) updated their AFib Guidelines to strongly
recommend using direct oral anticoagulants (DOACs), also called novel oral
anticoagulants (NOACs), over warfarin to prevent blood clots in people with
AFib. (2)
(1) Virani SS, et al. Heart Disease and Stroke Statistics-2021 Update: A Report from the American Heart Association. Circulation 2021. (2) Zimetbaum P. DOACs now recommended over warfarin to prevent blood clots in people with atrial fibrillation. Harvard Health Publishing 2019.
Agenda
- Spotlight Series: Improving Outcomes for Patients with Atrial Fibrillation - presentation
- Q & A
Presenter – Rakesh Gopinathannair, MD, MA, FAHA, FACC, FHRS
Faculty
Rakesh
Gopinathannair, MD, MA, FAHA, FACC, FHRSCardiac EP Lab Director, Kansas City Heart Rhythm Institute
Professor of Medicine, University of Missouri-Columbia
Disclosure Policy
All persons in a position to control educational content of a CE activity provided by the American Heart Association must disclose to the audience all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The presence or absence of all financial relationships will be disclosed to the audience in activity materials. All unlabeled/unapproved uses of drugs or devices discussed will also be disclosed to the audience. All relevant financial relationships have been mitigated prior to the commencement of the activity.
Disclosures
The American Heart Association (AHA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its certified educational activities. All faculty, planners, and contributors in a position to control the content for an AHA sponsored activity are required to disclose to the activity audience any financial relationships regardless of the amount during the prior 24 months with (1) the manufacturer(s) of any ineligible company product(s) and/or interest(s) of ineligible companies regardless of relation to the content of the activity and (2) any ineligible company supporters of the activity. When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.
Rakesh Gopinathannair, MD, MA, FAHA, FACC, FHRS - Consultant/speaker: Abbott Medical, Boston Scientific, Biotronik, Zoll Medical; Advisory Board: Altathera, PaceMate (no compensation)
Accreditation Statement
ORIGINAL RELEASE DATE: 02/07/2023
TERMINATION DATE: 02/06/2024
LAST REVIEW DATE: November 2022
ACCREDITATION TERMS: Joint Accreditation: 02/07/2023 - 02/06/2024
In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AMA Credit Designation Statement – Physicians
The American Heart Association designates this enduring activity for a
maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
MOC Statement
Successful completion of this CE activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.75 MOC
points in the American Board of Internal Medicine's (ABIM) Maintenance of
Certification (MOC) program. Participants will earn MOC points equivalent to
the amount of CE credits claimed for the activity. It is the CE activity
provider's responsibility to submit participant completion information to
ACCME for the purpose of granting ABIM MOC credit.
AAPA Credit Acceptance Statement – Physician
Assistants
AAPA accepts certificates of participation for educational activities
certified for AMA PRA Category 1 Credit™ from organizations
accredited by ACCME or a recognized state medical society. Physician
assistants may receive a maximum of 0.75 hours of Category I credit for
completing this program.
AANP Credit Acceptance Statement – Nurse
Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA
Category 1 Credit™ from organizations accredited by the ACCME.
ANCC Credit Designation Statement – Nurses
The maximum number of hours awarded for this CE activity is 0.75 contact
hours.
ACPE Credit Designation Statement – Pharmacists
ACPE Credit: 0.75 Contact Hours. Universal Program
Number: JA0000134-0000-22-100-H04-P
Instructions for Receiving Credit
Participation and Successful
Completion
Successful completion of this CE activity includes the following:
- Register and view the course online.
- View the content in its entirety.
- Complete a post-test with a minimum score of 80%.
- Complete a survey of your learning experience.
- Claim your CME/CE Certificate.
Statement of Commercial Support
This activity is supported by an independent medical educational grant from Sanofi US.
Disclaimer Statement/Disclosure of Unlabeled Use
When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.
Contact Information for Questions About the Activity
Luci Ochoa, MBA
Program Manager, Professional Education, AHA National Center
luci.ochoa@heart.org
Spotlight Series: Unmet Needs in Hypertension Treatment Options
StartActivity Details
1.0 ABIM MOC point(s)
1.0 ANCC Contact Hour(s)
Expires: January 30, 2024
Accredited By
ACCME (AMA PRA Category 1 Credit™), ANCC
Target Audience
- General Cardiologists
- Nephrologists
- Hypertension Specialists
- Internal Medicine Physicians
- Primary Care/Family Medicine Physicians
- Physician Assistants involved in the care of patients with hypertension
- Nurse Practitioners involved in the care of patients with hypertension
- Nurses involved in the care of patients with hypertension
Learning Objectives
- Recognize established and emerging treatment options for patients with resistant hypertension.
- Identify healthcare disparities in care provided to patients with hypertension.
- Apply shared decision-making strategies to improve health equity by better engaging patients in health care decisions through the development of improved patient-provider communication skills.
Activity Description
Hypertension increases with age and treatment-resistant hypertension exists within the US population.
Participants in this activity will learn about treatment options for patients with resistant hypertension, how to address healthcare disparities in treatment and management, and shared decision-making strategies to improve health equity.
Statement of Educational Need
It is estimated 10.3 million US adults have apparent treatment-resistant hypertension.1 The overall goal of the intervention is to increase healthcare professionals’ (HCP) awareness, knowledge, and competence in managing unmet needs in hypertension treatment. AHA Lifelong Learning will achieve this goal by addressing educational needs and practice gaps that exist among a multidisciplinary team of HCPs involved in the care of patients with hypertension. The intervention will promote application of education into practice, providing learners with knowledge and skills they can put into practice immediately to impact patient outcomes.
- Carey RM, Sakhuja S, Calhoun DA, et al. Prevalence of Apparent Treatment-Resistant Hypertension in the United States. Hypertension. 2019;73(2):424-431
Agenda
- Spotlight Series: Unmet Needs in Hypertension Treatment Options - presentation
- Q & A
Presenter – Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
Faculty
Gerald S. Berenson Endowed Chair in Preventive Cardiology
Professor of Medicine, John W. Deming Department of Medicine
Tulane University School of Medicine
New Orleans, LA
Disclosure Policy
All persons in a position to control educational content of a CE activity provided by the American Heart Association must disclose to the audience all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The presence or absence of all financial relationships will be disclosed to the audience in activity materials. All unlabeled/unapproved uses of drugs or devices discussed will also be disclosed to the audience. All relevant financial relationships have been mitigated prior to the commencement of the activity.
Disclosures
The American Heart Association (AHA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its certified educational activities. All faculty, planners, and contributors in a position to control the content for an AHA sponsored activity are required to disclose to the activity audience any financial relationships regardless of the amount during the prior 24 months with (1) the manufacturer(s) of any ineligible company product(s) and/or interest(s) of ineligible companies regardless of relation to the content of the activity and (2) any ineligible company supporters of the activity. When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.
Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA – Consultant (Amgen, Novartis, Medtronic, Quantum Genomics, Janssen)
Accreditation Statement
ORIGINAL RELEASE DATE: 01/31/2023
TERMINATION DATE: 01/30/2024
LAST REVIEW DATE: November 2022
ACCREDITATION TERMS: Joint Accreditation: 01/31/2023 - 01/30/2024
In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AMA Credit Designation Statement – Physicians
The American Heart Association designates this enduring activity for a
maximum of 1.0 AMA PRA Category 1 Credits™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
MOC Statement
Successful completion of this CE activity, which includes participation in
the evaluation component, enables the participant to earn up to 1.0 MOC
points in the American Board of Internal Medicine's (ABIM) Maintenance of
Certification (MOC) program. Participants will earn MOC points equivalent to
the amount of CE credits claimed for the activity. It is the CE activity
provider's responsibility to submit participant completion information to
ACCME for the purpose of granting ABIM MOC credit.
AAPA Credit Acceptance Statement – Physician
Assistants
AAPA accepts certificates of participation for educational activities
certified for AMA PRA Category 1 Credit™ from
organizations accredited by ACCME or a recognized state medical society.
Physician assistants may receive a maximum of 1.0 hours of Category I credit
for completing this program.
AANP Credit Acceptance Statement – Nurse
Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA
Category 1 Credit™ from organizations accredited by the ACCME.
ANCC Credit Designation Statement – Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact
hours.
Instructions for Receiving Credit
Participation and Successful
Completion
Successful completion of this CE activity includes the following:
- Register and view the course online.
- View the content in its entirety.
- Complete a post-test with a minimum score of 80%.
- Complete a survey of your learning experience.
- Claim your CME/CE Certificate.
Statement of Commercial Support
This activity is supported by an independent medical educational grant from Medtronic.
Disclaimer Statement/Disclosure of Unlabeled Use
When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.
Contact Information for Questions About the Activity
Luci Ochoa, MBA
Program Manager, Professional Education, AHA National Center
luci.ochoa@heart.org
Activity Details
1.0 ABIM MOC point(s)
1.0 ANCC Contact Hour(s)
Expires: January 30, 2024
Accredited By
ACCME (AMA PRA Category 1 Credit™), ANCC
Target Audience
- General Cardiologists
- Nephrologists
- Hypertension Specialists
- Internal Medicine Physicians
- Primary Care/Family Medicine Physicians
- Physician Assistants involved in the care of patients with hypertension
- Nurse Practitioners involved in the care of patients with hypertension
- Nurses involved in the care of patients with hypertension
Learning Objectives
- Recognize established and emerging treatment options for patients with resistant hypertension.
- Identify healthcare disparities in care provided to patients with hypertension.
- Apply shared decision-making strategies to improve health equity by better engaging patients in health care decisions through the development of improved patient-provider communication skills.
Activity Description
Hypertension increases with age and treatment-resistant hypertension exists within the US population.
Participants in this activity will learn about treatment options for patients with resistant hypertension, how to address healthcare disparities in treatment and management, and shared decision-making strategies to improve health equity.
Statement of Educational Need
It is estimated 10.3 million US adults have apparent treatment-resistant hypertension.1 The overall goal of the intervention is to increase healthcare professionals’ (HCP) awareness, knowledge, and competence in managing unmet needs in hypertension treatment. AHA Lifelong Learning will achieve this goal by addressing educational needs and practice gaps that exist among a multidisciplinary team of HCPs involved in the care of patients with hypertension. The intervention will promote application of education into practice, providing learners with knowledge and skills they can put into practice immediately to impact patient outcomes.
- Carey RM, Sakhuja S, Calhoun DA, et al. Prevalence of Apparent Treatment-Resistant Hypertension in the United States. Hypertension. 2019;73(2):424-431
Agenda
- Spotlight Series: Unmet Needs in Hypertension Treatment Options - presentation
- Q & A
Presenter – Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
Faculty
Gerald S. Berenson Endowed Chair in Preventive Cardiology
Professor of Medicine, John W. Deming Department of Medicine
Tulane University School of Medicine
New Orleans, LA
Disclosure Policy
All persons in a position to control educational content of a CE activity provided by the American Heart Association must disclose to the audience all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The presence or absence of all financial relationships will be disclosed to the audience in activity materials. All unlabeled/unapproved uses of drugs or devices discussed will also be disclosed to the audience. All relevant financial relationships have been mitigated prior to the commencement of the activity.
Disclosures
The American Heart Association (AHA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its certified educational activities. All faculty, planners, and contributors in a position to control the content for an AHA sponsored activity are required to disclose to the activity audience any financial relationships regardless of the amount during the prior 24 months with (1) the manufacturer(s) of any ineligible company product(s) and/or interest(s) of ineligible companies regardless of relation to the content of the activity and (2) any ineligible company supporters of the activity. When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.
Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA – Consultant (Amgen, Novartis, Medtronic, Quantum Genomics, Janssen)
Accreditation Statement
ORIGINAL RELEASE DATE: 01/31/2023
TERMINATION DATE: 01/30/2024
LAST REVIEW DATE: November 2022
ACCREDITATION TERMS: Joint Accreditation: 01/31/2023 - 01/30/2024
In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AMA Credit Designation Statement – Physicians
The American Heart Association designates this enduring activity for a
maximum of 1.0 AMA PRA Category 1 Credits™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
MOC Statement
Successful completion of this CE activity, which includes participation in
the evaluation component, enables the participant to earn up to 1.0 MOC
points in the American Board of Internal Medicine's (ABIM) Maintenance of
Certification (MOC) program. Participants will earn MOC points equivalent to
the amount of CE credits claimed for the activity. It is the CE activity
provider's responsibility to submit participant completion information to
ACCME for the purpose of granting ABIM MOC credit.
AAPA Credit Acceptance Statement – Physician
Assistants
AAPA accepts certificates of participation for educational activities
certified for AMA PRA Category 1 Credit™ from
organizations accredited by ACCME or a recognized state medical society.
Physician assistants may receive a maximum of 1.0 hours of Category I credit
for completing this program.
AANP Credit Acceptance Statement – Nurse
Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA
Category 1 Credit™ from organizations accredited by the ACCME.
ANCC Credit Designation Statement – Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact
hours.
Instructions for Receiving Credit
Participation and Successful
Completion
Successful completion of this CE activity includes the following:
- Register and view the course online.
- View the content in its entirety.
- Complete a post-test with a minimum score of 80%.
- Complete a survey of your learning experience.
- Claim your CME/CE Certificate.
Statement of Commercial Support
This activity is supported by an independent medical educational grant from Medtronic.
Disclaimer Statement/Disclosure of Unlabeled Use
When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.
Contact Information for Questions About the Activity
Luci Ochoa, MBA
Program Manager, Professional Education, AHA National Center
luci.ochoa@heart.org